| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:49 UTC |
|---|
| Update Date | 2022-03-07 02:51:35 UTC |
|---|
| HMDB ID | HMDB0014372 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Lovastatin |
|---|
| Description | Lovastatin is a cholesterol-lowering agent that belongs to the class of medications called statins. It was the second agent of this class discovered. It was discovered by Alfred Alberts and his team at Merck in 1978 after screening only 18 compounds over 2 weeks. The agent, also known as mevinolin, was isolated from the fungi Aspergillus terreus. Research on this compound was suddenly shut down in 1980 and the drug was not approved until 1987. Interesting, Akira Endo at Sankyo Co. (Japan) patented lovastatin isolated from Monascus ruber four months before Merck. Lovastatin was found to be 2 times more potent than its predecessor, mevastatin, the first discovered statin. Like mevastatin, lovastatin is structurally similar to hydroxymethylglutarate (HMG), a substituent of HMG-Coenzyme A (HMG-CoA), a substrate of the cholesterol biosynthesis pathway via the mevalonic acid pathway. Lovastatin is a competitive inhibitor of HMG-CoA reductase with a binding affinity 20,000 times greater than HMG-CoA. Lovastatin differs structurally from mevastatin by a single methyl group at the 6 position. Lovastatin is a prodrug that is activated by in vivo hydrolysis of the lactone ring. It, along with mevastatin, has served as one of the lead compounds for the development of the synthetic compounds used today. |
|---|
| Structure | [H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC InChI=1S/C24H36O5/c1-5-15(3)24(27)29-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-19-12-18(25)13-22(26)28-19/h6-7,10,14-16,18-21,23,25H,5,8-9,11-13H2,1-4H3/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (1S,3R,7S,8S,8AR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(2R,4R)-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl (S)-2-methyl-butyrate | ChEBI | | 2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone | ChEBI | | 6alpha-Methylcompactin | ChEBI | | Mevacor | ChEBI | | Mevinolin | ChEBI | | MK-803 | ChEBI | | ML-530b | ChEBI | | (1S,3R,7S,8S,8AR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(2R,4R)-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl (S)-2-methyl-butyric acid | Generator | | 2b,6a-Dimethyl-8a-(2-methyl-1-oxobutoxy)-mevinate lactone | Generator | | 2b,6a-Dimethyl-8a-(2-methyl-1-oxobutoxy)-mevinic acid lactone | Generator | | 2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinate lactone | Generator | | 2Β,6α-dimethyl-8α-(2-methyl-1-oxobutoxy)-mevinate lactone | Generator | | 2Β,6α-dimethyl-8α-(2-methyl-1-oxobutoxy)-mevinic acid lactone | Generator | | 6a-Methylcompactin | Generator | | 6Α-methylcompactin | Generator | | 6 alpha-Methylcompactin | HMDB | | 1 alpha-Isomer lovastatin | HMDB | | 6 Methylcompactin | HMDB | | 6-Methylcompactin | HMDB | | Lovastatin, 1 alpha-isomer | HMDB | | alpha-Isomer lovastatin, 1 | HMDB | | Lovastatin, (1 alpha(s*))-isomer | HMDB | | Lovastatin, 1 alpha isomer | HMDB | | Monacolin K | HMDB |
|
|---|
| Chemical Formula | C24H36O5 |
|---|
| Average Molecular Weight | 404.5396 |
|---|
| Monoisotopic Molecular Weight | 404.256274262 |
|---|
| IUPAC Name | (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate |
|---|
| Traditional Name | lovastatin |
|---|
| CAS Registry Number | 75330-75-5 |
|---|
| SMILES | [H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC |
|---|
| InChI Identifier | InChI=1S/C24H36O5/c1-5-15(3)24(27)29-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-19-12-18(25)13-22(26)28-19/h6-7,10,14-16,18-21,23,25H,5,8-9,11-13H2,1-4H3/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1 |
|---|
| InChI Key | PCZOHLXUXFIOCF-BXMDZJJMSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as delta valerolactones. These are cyclic organic compounds containing an oxan-2- one moiety. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Lactones |
|---|
| Sub Class | Delta valerolactones |
|---|
| Direct Parent | Delta valerolactones |
|---|
| Alternative Parents | |
|---|
| Substituents | - Delta valerolactone
- Fatty acid ester
- Delta_valerolactone
- Dicarboxylic acid or derivatives
- Oxane
- Fatty acyl
- Carboxylic acid ester
- Secondary alcohol
- Carboxylic acid derivative
- Oxacycle
- Organooxygen compound
- Hydrocarbon derivative
- Organic oxide
- Alcohol
- Organic oxygen compound
- Carbonyl group
- Aliphatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aliphatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 174.5 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.024 g/L | Not Available | | LogP | 4.5 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 7.89 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 20.2522 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 0.72 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 3387.6 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 471.2 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 232.1 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 190.6 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 241.8 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 922.8 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 892.5 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 83.1 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1685.2 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 667.0 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1868.2 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 515.4 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 510.3 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 219.7 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 406.1 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 8.4 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized |
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental GC-MS | GC-MS Spectrum - Lovastatin EI-B (Non-derivatized) | splash10-0a4i-2910000000-dc8caf3905a76d1dc259 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | | Experimental GC-MS | GC-MS Spectrum - Lovastatin EI-B (Non-derivatized) | splash10-0a4j-1910000000-8aeacab386a420581150 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | | Experimental GC-MS | GC-MS Spectrum - Lovastatin EI-B (Non-derivatized) | splash10-0a4i-2910000000-dc8caf3905a76d1dc259 | 2018-05-18 | HMDB team, MONA, MassBank | View Spectrum | | Experimental GC-MS | GC-MS Spectrum - Lovastatin EI-B (Non-derivatized) | splash10-0a4j-1910000000-8aeacab386a420581150 | 2018-05-18 | HMDB team, MONA, MassBank | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Lovastatin GC-MS (Non-derivatized) - 70eV, Positive | splash10-0a4r-9155000000-825da9f6a87f5a59c1c2 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Lovastatin GC-MS (1 TMS) - 70eV, Positive | splash10-03di-9137500000-a125220abcd76ffa9a89 | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Lovastatin GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Lovastatin GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Lovastatin LC-ESI-qTof , Positive-QTOF | splash10-000i-0049000000-86650e3e374df663aa35 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lovastatin LC-ESI-qTof , Positive-QTOF | splash10-000i-0049000000-86650e3e374df663aa35 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lovastatin LC-ESI-qTof , Positive-QTOF | splash10-017j-3981000000-8a9df18d5a3d8401a040 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lovastatin LC-ESI-QTOF , positive-QTOF | splash10-0k9j-0392200000-046f8ecdd9105ec8f133 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lovastatin LC-ESI-QTOF , positive-QTOF | splash10-0fg2-0590000000-79f2e6dc3b230361fea3 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lovastatin LC-ESI-QTOF , positive-QTOF | splash10-0092-0970000000-029f3798d63ab95ed321 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lovastatin LC-ESI-QTOF , positive-QTOF | splash10-0592-0930000000-85de8f33dd78ba45de36 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lovastatin LC-ESI-QTOF , positive-QTOF | splash10-05fv-0910000000-7a730b8fcd91e3df5b8f | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lovastatin LC-ESI-QFT , positive-QTOF | splash10-000e-0590000000-2206c97b74e146b3218d | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lovastatin LC-ESI-QFT , positive-QTOF | splash10-0092-1960000000-6b3a14df210273b89f18 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lovastatin LC-ESI-QFT , positive-QTOF | splash10-0592-1910000000-38bd634327305fe325cf | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lovastatin LC-ESI-QFT , positive-QTOF | splash10-0abd-1900000000-e7dab133ffe03d435831 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lovastatin LC-ESI-QFT , positive-QTOF | splash10-0536-2900000000-12e639483c7d1a83da05 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lovastatin LC-ESI-QFT , positive-QTOF | splash10-002f-2900000000-ed64daa9de830f1f3cb0 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lovastatin 30V, Positive-QTOF | splash10-0092-0960000000-cb24a6eb72478d051b37 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lovastatin 10V, Positive-QTOF | splash10-0k9j-0392200000-046f8ecdd9105ec8f133 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lovastatin 50V, Positive-QTOF | splash10-0597-0910000000-87327bc487bcb23a89f1 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lovastatin 20V, Positive-QTOF | splash10-000b-0590000000-c8c50c20a62e59420cf2 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lovastatin 50V, Positive-QTOF | splash10-05fv-0910000000-d4c442d499341c3a56f4 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lovastatin 10V, Positive-QTOF | splash10-052r-2019200000-72562315d7aa45f51111 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lovastatin 20V, Positive-QTOF | splash10-0f79-9176000000-32a60aba487dd125aab1 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lovastatin 40V, Positive-QTOF | splash10-052r-9130000000-effc5ee7a79a5469060c | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lovastatin 10V, Negative-QTOF | splash10-0udi-0009500000-03828e23d026b9da8a74 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lovastatin 20V, Negative-QTOF | splash10-100r-5219100000-bd7b9834593ecb989122 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lovastatin 40V, Negative-QTOF | splash10-0006-9132000000-6ad0a599a6d123e8d3bb | 2016-08-03 | Wishart Lab | View Spectrum |
|
|---|